Myeloma | Tumor

CURE’s myeloma page is a go-to resource for oncology news and updates in the world of myeloma Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in myeloma.

Educated Patient® Multiple Myeloma Summit Precision Medicine Presentation: November 13, 2022

December 8th 2022

Watch Dr. Marcella Kaddoura, from Miami Sylvester Comprehensive Cancer Center, discuss targeting myeloma with small molecules with precision medicine during the CURE® Educated Patient® Multiple Myeloma Summit.

Educated Patient® Multiple Myeloma Summit Predicting Clinical Outcomes Presentation: November 13, 2022

December 7th 2022

Watch Dr. Francesco Maura, from Miami Sylvester Comprehensive Cancer Center, discuss how personalized prediction models can be used to identify the best treatments during the CURE® Educated Patient Multiple Myeloma Summit.

Educated Patient® Multiple Myeloma Summit Treating Myeloma Long-Term Panel: November 13, 2022

December 6th 2022

Watch Valarie Traynham, of the HealthTree Foundation, discuss the long-term journey of the disease and disparities still seen during the CURE® Educated Patient® Multiple Myeloma Summit.

Educated Patient® Multiple Myeloma Summit Therapy and Beyond Panel: November 13, 2022

December 5th 2022

Watch Dr. Dickran Kazandjian and Dr. Benjamin Diamond answer questions about therapeutic options during the CURE® Educated Patient® Multiple Myeloma Summit.

Educated Patient® Multiple Myeloma Summit Role of Sustained MRD Negativity Presentation: November 13, 2022

December 4th 2022

Watch Dr. Benjamin T. Diamond, from Sylvester Comprehensive Cancer Center at the University of Miami, discuss the role of sustained MRD negativity during the CURE® Educated Patient® Multiple Myeloma Summit.

Educated Patient® Multiple Myeloma Summit Immunotherapy Presentation: November 13, 2022

December 3rd 2022

Watch Dr. Dickran Kazandjian, from the Sylvester Comprehensive Cancer Center at the University of Miami, discuss available immunotherapy options during the CURE® Educated Patient® Multiple Myeloma Summit.

Educated Patient® Multiple Myeloma Summit Disease Overview Panel: November 13, 2022

December 2nd 2022

Watch Dr. C. Ola Landgren and Dr. David Coffey answer questions about novel treatments and the role of a healthy immune system during the CURE® Educated Patient® Multiple Myeloma Summit.

Educated Patient® Multiple Myeloma Summit Role of the Healthy Immune System Presentation: November 13, 2022

December 1st 2022

Watch Dr. David Coffey, from Sylvester Comprehensive Cancer Center at the University of Miami, discuss the role of a healthy immune system during the CURE® Educated Patient® Multiple Myeloma Summit.

Educated Patient® Multiple Myeloma Summit Novel Treatments for the Newly Diagnosed Presentation: November 13, 2022

November 30th 2022

Watch Dr. C. Ola Landgren, from Sylvester Comprehensive Cancer Center at the University of Miami, discuss novel treatments for newly diagnosed patients during the CURE® Educated Patient® Multiple Myeloma Summit.

Finding Support During a Multiple Myeloma Diagnosis

November 21st 2022

As a part of its “Speaking Out” video series, on behalf of the International Myeloma Foundation, CURE® spoke with their vice president of support, Robin Tuohy about the importance of support for patients with multiple myeloma, and their caregivers.

The Basics of Clinical Trials for Patients with Multiple Myeloma

November 21st 2022

As a part of its “Speaking Out” video series, on behalf of the International Myeloma Foundation, CURE® spoke with their chief medical officer, Dr. Joseph Mikhael about clinical trials for patients with multiple myeloma.

Spotlighting Disparities in Multiple Myeloma

November 21st 2022

As a part of its “Speaking Out” video series, on behalf of the International Myeloma Foundation, CURE® spoke with their chief medical officer, Dr. Joseph Mikhael about disparities in the multiple myeloma space.

Treating, Monitoring and Understanding Myeloma Precursors, MGUS and Smoldering Myeloma

November 21st 2022

As a part of its “Speaking Out” video series, on behalf of the International Myeloma Foundation, CURE® spoke with their chief medical officer, Dr. Joseph Mikhael about the precursors to multiple myeloma, MGUS and smoldering myeloma.

Managing the Risk of Infection for Patients with Multiple Myeloma

November 21st 2022

As a part of its “Speaking Out” video series, on behalf of the International Myeloma Foundation, CURE® spoke with their chief medical officer, Dr. Joseph Mikhael about the risk of infection for patients with multiple myeloma.

Tecvayli Is a Quicker and ‘More Convenient’ Treatment for Myeloma, But Limited Hospital Space Highlights the Need for Outpatient Therapies

November 17th 2022

Tecvayli, which was recently approved for pretreated relapsed/refractory myeloma, is a “much more convenient” treatment option than CAR-T cell therapy, one expert said.

FDA to Review Aphexda in the Transplant Setting for Patients with Multiple Myeloma

November 13th 2022

Aphexda was well tolerated and helped the majority of patients collect enough cells to go to transplant, study results showed.

Blenrep Misses Main Study Goal for Patients with Relapsed/Refractory Multiple Myeloma

November 8th 2022

Blenrep did not meet its progression-free survival endpoint in a phase 3 clinical trial for patients with relapsed or refractory multiple myeloma.

Altered Taste After Stem Cell Transplants for Multiple Myeloma May Negatively Affect Daily Calorie Intake, Quality of Life

November 3rd 2022

Stem cell transplants may cause dysgeusia — a disorder that alters a person’s taste —in some patients with multiple myeloma, which is a type of blood cancer. This disorder may have a domino effect on quality of life, although levels may return to normal a few months after the procedure, an expert said.

FDA Approves Tecvayli for Relapsed/Refractory Myeloma

October 25th 2022

The FDA’s approval of Tecvayli was based on findings showing that 61.8% of patients with pretreated, relapsed/refractory myeloma responded to the drug.

How a Hike on Mount Everest to Raise Awareness, Funds for Blood Cancer Forever Changed the Lives of the Participants

October 10th 2022

In 2018, 18 trekkers completed an awe-inspiring hike of the Himalayan highlands to the doorstep of the world’s tallest mountain, Mount Everest, to raise awareness and funding for multiple myeloma, a type of blood cancer. Three of the climbers discuss a bond that hasn’t broken.

FDA Panel Votes Against Continued Approval of Pepaxto for Myeloma Subtype

September 28th 2022

The FDA’s Oncologic Drugs Advisory Committee voted against the continued approval of Pepaxto for pretreated relapsed/refractory myeloma, based on survival data from a clinical trial.

Sarclisa Delivered Through Under-the-Skin Injection Shows Promise in Patients With Pretreated Myeloma

September 1st 2022

Delivering Sarclisa via an under-the-skin injection may improve the quality of life of patients with pretreated relapsed, refractory multiple myeloma, according to recent research.

‘Mounting Evidence’ Suggests Exposure to Environmental Toxins Plays a Role in Onset of Myeloma, Says Expert

August 29th 2022

Firefighters and recovery workers exposed to the aftermath of 9/11 in New York City had a higher occurrence of MGUS, a condition which may progress to myeloma, according to recent research.

Addition of Empliciti to Combination Regimen Continues to Show Benefit in Previously Treated Multiple Myeloma

August 29th 2022

Long-term follow-up shows that treatment with Empliciti plus pomalidomide and dexamethasone continues to significantly increase survival rates in patients with relapsed or refractory multiple myeloma, a persistent cancer affecting white blood cells that may be resistant to treatment.

The Hub of Our Oncology Program

August 28th 2022

Lisa’s excellent fund of knowledge, experience in oncology, outstanding judgment and interest in learning all make her a truly outstanding clinician.

Use of Potentially Inappropriate Medications Associated With Increased Risks for Poor Outcomes in Older Patients With Cancer

August 11th 2022

The use of five or more medicines — as well as some drugs that could be deemed inappropriate — may put older patients with cancer at a higher risk for complications, such as weakness.

Abecma Improves Progression-Free Survival in Relapsed/Refractory Multiple Myeloma

August 10th 2022

Data from a clinical trial demonstrate a “clear clinical benefit” of using a CAR-T cell therapy in patients with multiple myeloma, according to the drugs manufacturer.

COVID-19 Booster Sparks Antibody Response in Patients With Blood Cancer Who Didn’t Benefit from Initial Vaccination

July 21st 2022

Findings from previous studies have shown that patients with blood cancers have been less likely to produce antibodies that protect them against COVID-19 after vaccination, but new research indicates that the booster shot may help.

New Drug Will Be Studied in Relapsed/Refractory Myeloma, Other Blood Cancers

July 6th 2022

The myeloma treatment group of the COVALENT-101 clinical trial recently started, analyzing the new drug BMF-219 in patients with relapsed or refractory disease.

Not Just My Oncology Nurse, But My Friend

July 4th 2022

She has helped me so much with my medications, and she always lifts me up when I need it most.

NEXT PAGE
PREVIOUS PAGE